Jean-Marie Stephan1, Michael J Goodheart2, Megan McDonald2, Jean Hansen2, Henry D Reyes2, Anna Button3, David Bender2. 1. Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA. Electronic address: Jean-marie-stephan@uiowa.edu. 2. Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA. 3. Department of Biostatistics, University of Iowa Hospitals and Clinics, Iowa City, IA.
Abstract
OBJECTIVE: Morbid obesity is a known risk factor for the development of endometrial cancer. Several studies have demonstrated the overall feasibility of robotic-assisted surgical staging for endometrial cancer as well as the benefits of robotics compared with laparotomy. However, there have been few reports that have evaluated robotic surgery for endometrial cancer in the supermorbidly obese population (body mass index [BMI], ≥50 kg/m(2)). We sought to evaluate safety, feasibility, and outcomes for supermorbidly obese patients who undergo robotic surgery for endometrial cancer, compared with patients with lower body mass indices. STUDY DESIGN: We performed a retrospective chart review of 168 patients with suspected early-stage endometrial adenocarcinoma who underwent robotic surgery for the management of their disease. Analysis of variance and univariate logistic regression were used to compare patient characteristics and surgical variables across all body weights. Cox proportional hazard regression was used to determine the impact of body weight on recurrence-free and overall survival. RESULTS: The mean BMI of our cohort was 40.9 kg/m(2). Median follow up was 31 months. Fifty-six patients, 30% of which had grade 2 or 3 tumors, were supermorbidly obese with a BMI of ≥50 kg/m(2) (mean, 56.3 kg/m(2)). A comparison between the supermorbidly obese and lower-weight patients demonstrated no differences in terms of length of hospital stay, blood loss, complication rates, numbers of pelvic and paraaortic lymph nodes retrieved, or recurrence and survival. There was a correlation between BMI and conversion to an open procedure, in which the odds of conversion increased with increasing BMI (P = .02). CONCLUSION: Offering robotic surgery to supermorbidly obese patients with endometrial cancer is a safe and feasible surgical management option. When compared with patients with a lower BMI, the supermorbidly obese patient had a similar outcome, length of hospital stay, blood loss, complications, and numbers of lymph nodes retrieved.
OBJECTIVE: Morbid obesity is a known risk factor for the development of endometrial cancer. Several studies have demonstrated the overall feasibility of robotic-assisted surgical staging for endometrial cancer as well as the benefits of robotics compared with laparotomy. However, there have been few reports that have evaluated robotic surgery for endometrial cancer in the supermorbidly obese population (body mass index [BMI], ≥50 kg/m(2)). We sought to evaluate safety, feasibility, and outcomes for supermorbidly obesepatients who undergo robotic surgery for endometrial cancer, compared with patients with lower body mass indices. STUDY DESIGN: We performed a retrospective chart review of 168 patients with suspected early-stage endometrial adenocarcinoma who underwent robotic surgery for the management of their disease. Analysis of variance and univariate logistic regression were used to compare patient characteristics and surgical variables across all body weights. Cox proportional hazard regression was used to determine the impact of body weight on recurrence-free and overall survival. RESULTS: The mean BMI of our cohort was 40.9 kg/m(2). Median follow up was 31 months. Fifty-six patients, 30% of which had grade 2 or 3 tumors, were supermorbidly obese with a BMI of ≥50 kg/m(2) (mean, 56.3 kg/m(2)). A comparison between the supermorbidly obese and lower-weight patients demonstrated no differences in terms of length of hospital stay, blood loss, complication rates, numbers of pelvic and paraaortic lymph nodes retrieved, or recurrence and survival. There was a correlation between BMI and conversion to an open procedure, in which the odds of conversion increased with increasing BMI (P = .02). CONCLUSION: Offering robotic surgery to supermorbidly obesepatients with endometrial cancer is a safe and feasible surgical management option. When compared with patients with a lower BMI, the supermorbidly obesepatient had a similar outcome, length of hospital stay, blood loss, complications, and numbers of lymph nodes retrieved.
Authors: Mario M Leitao; Wazim R Narain; Donna Boccamazzo; Vasileios Sioulas; Danielle Cassella; Jennifer A Ducie; Ane Gerda Z Eriksson; Yukio Sonoda; Dennis S Chi; Carol L Brown; Douglas A Levine; Elizabeth L Jewell; Oliver Zivanovic; Richard R Barakat; Nadeem R Abu-Rustum; Ginger J Gardner Journal: Ann Surg Oncol Date: 2016-01-07 Impact factor: 5.344
Authors: Deborah S Keller; Nisreen Madhoun; Juan Ramon Flores-Gonzalez; Sergio Ibarra; Reena Tahilramani; Eric M Haas Journal: J Gastrointest Surg Date: 2015-12-24 Impact factor: 3.452
Authors: Kristin Bixel; David A Barrington; Monica H Vetter; Adrian A Suarez; Ashley S Felix Journal: J Minim Invasive Gynecol Date: 2021-08-01 Impact factor: 4.137